Piramal Pharma Solutions will add a 4.3 MWp ground-mounted solar power plant at its integrated drug substance and drug product facility in Morpeth, UK. The behind-the-meter installation will supply approximately 3,950 MWh of renewable electricity annually, covering around 22% of the site’s electricity demand once operations begin in the first quarter of 2027. The project will use about 6,200 panels across 16 acres and is expected to generate enough electricity to power approximately 1,460 UK homes per year. Delivered under a Power Purchase Agreement with Alight UK BTM1 Limited, the plant is expected to help avoid an estimated 20,000 tCO₂e over 25 years. The project supports Piramal Pharma’s target of reducing Scope 1 and Scope 2 greenhouse gas emissions by 42% by FY2030 while strengthening energy resilience and managing onsite power costs.